Biodesix BDSX Stock
Biodesix Price Chart
Biodesix BDSX Financial and Trading Overview
Biodesix stock price | 0.58 USD |
Previous Close | 1.46 USD |
Open | 1.49 USD |
Bid | 0 USD x 3100 |
Ask | 0 USD x 3100 |
Day's Range | 1.44 - 1.55 USD |
52 Week Range | 0.96 - 3 USD |
Volume | 36.81K USD |
Avg. Volume | 67.88K USD |
Market Cap | 114.55M USD |
Beta (5Y Monthly) | 1.469848 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.33 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5 USD |
BDSX Valuation Measures
Enterprise Value | 125.07M USD |
Trailing P/E | N/A |
Forward P/E | -2.607143 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.8130782 |
Price/Book (mrq) | 25.172415 |
Enterprise Value/Revenue | 3.071 |
Enterprise Value/EBITDA | -2.552 |
Trading Information
Biodesix Stock Price History
Beta (5Y Monthly) | 1.469848 |
52-Week Change | 0.34% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3 USD |
52 Week Low | 0.96 USD |
50-Day Moving Average | 1.54 USD |
200-Day Moving Average | 1.65 USD |
BDSX Share Statistics
Avg. Volume (3 month) | 67.88K USD |
Avg. Daily Volume (10-Days) | 44.99K USD |
Shares Outstanding | 78.46M |
Float | 15.55M |
Short Ratio | 2.95 |
% Held by Insiders | 64.38% |
% Held by Institutions | 14.99% |
Shares Short | 211.48K |
Short % of Float | 0.69% |
Short % of Shares Outstanding | 0.27% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -168.37% |
Operating Margin (ttm) | -128.87% |
Gross Margin | 65.40% |
EBITDA Margin | -120.34% |
Management Effectiveness
Return on Assets (ttm) | -46.051% |
Return on Equity (ttm) | -1112.043% |
Income Statement
Revenue (ttm) | 40.72M USD |
Revenue Per Share (ttm) | 0.76 USD |
Quarterly Revenue Growth (yoy) | 38.29% |
Gross Profit (ttm) | 24.06M USD |
EBITDA | -49005000 USD |
Net Income Avi to Common (ttm) | -68563000 USD |
Diluted EPS (ttm) | -1.35 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 25.28M USD |
Total Cash Per Share (mrq) | 0.32 USD |
Total Debt (mrq) | 38.94M USD |
Total Debt/Equity (mrq) | 855.71 USD |
Current Ratio (mrq) | 1.574 |
Book Value Per Share (mrq) | 0.058 |
Cash Flow Statement
Operating Cash Flow (ttm) | -39559000 USD |
Levered Free Cash Flow (ttm) | -43486124 USD |
Profile of Biodesix
Country | United States |
State | CO |
City | Boulder |
Address | 2970 Wilderness Place |
ZIP | 80301 |
Phone | 303 417 0500 |
Website | https://www.biodesix.com |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 245 |
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Q&A For Biodesix Stock
What is a current BDSX stock price?
Biodesix BDSX stock price today per share is 0.58 USD.
How to purchase Biodesix stock?
You can buy BDSX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Biodesix?
The stock symbol or ticker of Biodesix is BDSX.
Which industry does the Biodesix company belong to?
The Biodesix industry is Diagnostics & Research.
How many shares does Biodesix have in circulation?
The max supply of Biodesix shares is 145.98M.
What is Biodesix Price to Earnings Ratio (PE Ratio)?
Biodesix PE Ratio is now.
What was Biodesix earnings per share over the trailing 12 months (TTM)?
Biodesix EPS is -0.33 USD over the trailing 12 months.
Which sector does the Biodesix company belong to?
The Biodesix sector is Healthcare.
Biodesix BDSX included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15404.92 USD — |
-1.17
|
5.29B USD — | 14784.03 USD — | 16292.28 USD — | — - | 5.29B USD — |
NASDAQ Global Market Composite NQGM | 1623.98 USD — |
-1.45
|
— — | 1547.55 USD — | 1705.12 USD — | — - | — — |
NASDAQ HealthCare IXHC | 858.4 USD — |
-1.31
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}